We recently published a list of 11 Blue Chip Stocks to Invest in at 52-Week Lows. In this article, we are going to take a ...

Regeneron (REGN) and Sanofi (SNY) announced that the Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing ...

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD Following recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results in adu ...

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils Approval marks the first new treatment approach for ...

We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we are going to look at where Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) ...

UNITY Biotechnology stock loses 29% as the mid-stage DME study of the lead candidate, UBX1325, fails to achieve statistical ...

We recently published a list of 11 Best Extremely Profitable Stocks to Buy According to Analysts. In this article, we are ...

The Eylea franchise was in need of a win after an appellate court last week denied the pharma’s bid to block Amgen’s ...

Opthea's sozinibercept and Unity's UBX1325 fail to match Regeneron's Eylea in separate eye disease trials; Opthea faces ...

Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary ...

Australian-US biotech Opthea Ltd has reported disappointing phase 3 results with its lead drug for vision-robbing disease wet age-related macular degeneration (AMD), throwing its future into doubt.